MAP1LC3A and hepatocellular carcinoma: Patients with low Axl and high LC3 expression in tumors had 1‐, 3‐, 5‐ and 7‐year HCC recurrence rates of 3.2%, 15.9%, 34.9% and 50.4%, respectively.